Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Financial performance
Oncology
Innovation: Pipeline overview
Financial review
Conclusion
Strong FY operational performance from growth drivers
Key growth driver sales FY 20211
Driving portfolio rejuvenation
Appendix
Innovation: Clinical trials
Sales
USD Million
Growth vs. PY
Growth vs. PY
USD Million
CC
Key growth drivers 52% of IM sales, growing 25% vs. PY
Entresto
sacubitrill/valsartan
3,548
1,051 40%
AimovigⓇ
52%
Cosentyx
4,718
723
17%
MayzentⓇ
(secukinumab)
Piqray®
zolgensma 1,351
431
46%
44%
Kesimpta
372
357
nm
(ofatumumab)
35%
PROMACTA
(eltrombopag)
2,016
278
15%
JAKAVI®
1,595
256
16%
27%
KesimptaⓇ
XiidraⓇ
LutatheraⓇ
KymriahⓇ
KisqaliⓇ
ruxolitinib
KISQALI
937
250
36%
ribociclib
ILARIS
1,059
186
22%
(canakinumab)
Xolair
1,428
177
12%
Omalizumab
SUBGYGARDOS OS
llarisⓇ
ZolgensmaⓇ
JakaviⓇ
Tafinlar+Mekinist®
Promacta®
EntrestoⓇ
Tafinlar +Mekinist
1,693
151
8%
beb
KYMRIAH
587
113
22%
(tisagenlecleucel) fin
MAYZENT.
281
111
CosentyxⓇ
Other²
FY 2018
FY 2019
FY 2020
FY 2021
65%
(siponimod) tablets
nm - not meaningful
1. Innovative Medicines division. 2. Includes Xolair®, Beovu ®, Adakveo®, Tabrecta Ⓡ, Luxturna®, Enerzair ®, Atectura ®, LeqvioⓇ and ScemblixⓇ. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An
explanation of non-IFRS measures can be found on page 49 of the Condensed Financial Report.
52 Investor Relations | Q4 2021 Results
U NOVARTIS | Reimagining MedicineView entire presentation